Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Deferred Tax Liability (2023 - 2025)

Perspective Therapeutics (CATX) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 31.78% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 31.78% year-over-year, with the annual reading at $1.7 million for FY2025, 31.78% down from the prior year.
  • Non-Current Deferred Tax Liability hit $1.7 million in Q4 2025 for Perspective Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.6 million in Q4 2023 to a low of $1.7 million in Q4 2025.
  • Historically, Non-Current Deferred Tax Liability has averaged $3.3 million across 3 years, with a median of $2.5 million in 2024.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: crashed 45.67% in 2024 and later crashed 31.78% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $4.6 million in 2023, then plummeted by 45.67% to $2.5 million in 2024, then plummeted by 31.78% to $1.7 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for CATX at $1.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.5 million in Q2 2025.